Natural compound that act like an ideal male contraceptive has been identified by the Lundquist Institute researchers.
New natural compound is a safe, effective and reversible male contraceptive agent in pre-clinical animal models, as per the research published by Nature Communications by The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.
‘Triptonide is a highly promising non-hormonal male contraceptive agent for men. It has good bioavailability, efficacy, reversibility and safety.’
Read More..
The compound is triptonide, which can be either purified from a Chinese herb called Tripterygium Wilfordii Hook F, or produced through chemical synthesis. Single daily oral doses of triptonide induce altered sperm having minimal or no forward motility with close to 100% penetrance and consequently male infertility in 3-4 and 5-6 weeks.Read More..
Once the treatment is stopped, the males become fertile again in ~4-6 weeks, and can produce healthy offspring. No discernable toxic effects were detected in either short- or long-term triptonide treatment.
All of their data suggest that triptonide is a highly promising non-hormonal male contraceptive agent for men because it appears to meet all of the criteria for a viable contraceptive drug candidate, including bioavailability, efficacy, reversibility and safety.
A battery of biochemical analyses suggest that triptonide targets one of the last steps during sperm assembly, leading to the production of altered sperm without vigorous motility required for fertilization.
"Thanks to decades of basic research, which inspired us to develop the idea that a compound that targets a protein critical for the last several steps of sperm assembly would lead to the production of nonfunctional sperm without causing severe depletion of testicular cells", said Dr. Yan.
Advertisement
"Dr. Yan's discovery represents a major leap forward in the field", said Drs. Christina Wang and Ronald Swerdloff, who are TLI co-Principal Investigators helping lead NIH-supported advanced clinical trials on hormone-based birth control approaches.
Advertisement
Source-Eurekalert